Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain

被引:0
作者
Bernd Lange
Brigitte Kuperwasser
Akiko Okamoto
Achim Steup
Thomas Häufel
Judy Ashworth
Mila Etropolski
机构
[1] Global Development,
[2] Grünenthal GmbH,undefined
[3] Johnson & Johnson Pharmaceutical Research & Development,undefined
来源
Advances in Therapy | 2010年 / 27卷
关键词
chronic pain; EQ-5D; low back pain; opioid responder rates; opioid tolerability; osteoarthritis; oxycodone controlled release; quality of life; tapentadol prolonged release; SF-36; treatment discontinuation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:381 / 399
页数:18
相关论文
共 63 条
[1]  
Hale M.E.(1999)Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain Clin J Pain 15 179-183
[2]  
Fleischmann R.(2005)Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study J Pain 6 21-28
[3]  
Salzman R.(2007)A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain Curr Med Res Opin 23 117-128
[4]  
Hale M.E.(2007)Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study Clin J Pain 23 287-299
[5]  
Dvergsten C.(2006)The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain J Opioid Manag 2 155-166
[6]  
Gimbel J.(2007)Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis Clin Ther 29 874-888
[7]  
Katz N.(2005)Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial Pain Med 6 357-366
[8]  
Rauck R.(2000)Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation Arch Intern Med 160 853-860
[9]  
Ahdieh H.(2004)Opioids in chronic non-cancer pain: systematic review of efficacy and safety Pain 112 372-380
[10]  
Portenoy R.K.(2008)Opioid complications and side effects Pain Physician 11 S105-S120